Targeting individual calpain isoforms for neuroprotection.
Targeting individual calpain isoforms for neuroprotection.
复制标题
DOI:
10.1016/j.expneurol.2010.07.025
复制
发表时间:
2010-11
影响因子:
5.3
通讯作者:
Saatman, Kathryn E.
中科院分区:
文献类型:
--
作者:
Geddes, James W.;Saatman, Kathryn E.
Calpain overactivation is implicated in the neurodegeneration resulting from a wide range of neurologic disorders and neurodegen-erative conditions including stroke, traumatic brain and spinal cord injury, and Alzheimer’s disease (Bevers and Neumar, 2008; Saatman et al., 2010; Vosler et al., 2008). The best-characterized calpains, and those predominant in the CNS, are the ubiquitous m-and μ-calpains. A major difference between these two isoforms is the Ca2+ requirement of the purified enzymes, with m-calpain requiring millimolar Ca2+ for activation as compared to micromolar Ca2+ for μ-calpain (Dayton, 1982). Other calpains present in the CNS include 3, 5, 10, and 12 (Konig et al., 2003; Ma et al., 2001; Shin et al., 2004; Waghray et al., 2004), although their roles and relative activities are largely unknown.While calpain overactivation contributes to neurodegeneration, calpains also serve essential physiological roles including signal transduction, cell migration, membrane fusion, and cell differentiation. Thus, the challenge is to inhibit the pathological consequences of calpain overactivation but preserve physiologic aspects of calpain function. One approach is to identify calpain isoforms with a prominent pathological role, as opposed to those which are essential for physiological calpain functions. The high Ca2+ levels required to activate mcalpain would presumably only be encountered under pathologic conditions; therefore mcalpain has been hypothesized to represent a pathologic isoform. However, m-calpain may be activated by much lower Ca2+ levels in vivo or by non-Ca2+ mechanisms including trophic factors (Goll et al., 2003; Zadran et al., 2010). Alternatively, support for μ-calpain as a pathologic isoform was based on its distribution and that of its cleaved substrate, αII-spectrin, following CNS insults (Grynspan et al., 1997; Hamakubo et al., 1986; Roberts-Lewis et al., 1994; Siman et al., 1985). However, the substrates of the two calpain isoforms are highly similar, at least in vitro, and small molecule calpain inhibitors inhibit both isoforms with similar potency (Goll et al., 2003; Wang and Yuen, 1999). As a result, it has been difficult to identify distinct roles for these two ubiquitous calpain isoforms.
登录
查看更多内容
影响因子:
4.7
作者:
Bevers, Matthew B.;Lawrence, Eric;Neumar, Robert W.
通讯作者:
Neumar, Robert W.
影响因子:
2.8
作者:
König, N;Raynaud, F;Benyamin, Y
通讯作者:
Benyamin, Y
影响因子:
4.8
作者:
Zhang, WL;Lane, RD;Mellgren, RL
通讯作者:
Mellgren, RL
DOI:
10.1016/j.nurt.2009.11.002
发表时间:
2010-01
期刊:
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
影响因子:
--
作者:
Saatman KE;Creed J;Raghupathi R
通讯作者:
Raghupathi R
DOI:
10.1523/jneurosci.5120-09.2010
发表时间:
2010-01-20
期刊:
The Journal of neuroscience : the official journal of the Society for Neuroscience
影响因子:
--
作者:
Zadran S;Jourdi H;Rostamiani K;Qin Q;Bi X;Baudry M
通讯作者:
Baudry M